Clinical Trial
Efficacy of Transcranial Static Magnetic Field Stimulation (tSMS) and Potential Theranostic Biomarkers in Amyotrophic Lateral Sclerosis (ALS).
ClinicalTrials.gov12/2/2024·12/02/24🌐 Europe
Summary
This study evaluates transcranial static magnetic field stimulation (tSMS) as a potential theranostic biomarker in amyotrophic lateral sclerosis. The non-invasive device applies static magnetic fields to the motor cortex to assess cortical excitability changes and their correlation with disease progression markers.
Why it matters
tSMS is an emerging neuromodulation technology that requires no power source and is completely silent during application. As a theranostic tool, it could provide both therapeutic benefit and real-time biomarker data to track ALS progression non-invasively.
#Phase 2#ALS#Neurostimulation#TMS#Non-invasive#Neurodiagnostics#Biomarkers#Europe
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trialAlready a member? Sign in